Moderna Soars 177% After Melanoma Vaccine Clears Phase 3 Trial on August 20

Moderna (NASDAQ: MRNA) surged 177% to $174.38 on August 19 after announcing that its experimental cancer vaccine intismeran met primary endpoints in a Phase 3 melanoma trial. The personalized mRNA therapy, developed with Merck, reduced cancer recurrence and spread in 1,137 patients when combined with Merck’s immunotherapy Keytruda. This marks the first positive late-stage trial for an mRNA-based cancer treatment, a watershed moment for the biotech sector.

What the trial showed

The INTerpath-001 study evaluated intismeran plus Keytruda versus Keytruda alone in patients with surgically removed stage IIB-IV melanoma. The combination significantly extended recurrence-free survival and reduced distant metastasis risk compared to standard care. Merck’s stock climbed 12% on the news, while Moderna’s 177% jump reflects its smaller $25 billion market cap versus Merck’s $333 billion.

How the personalized vaccine works

Intismeran is a neoantigen therapy that sequences each patient’s tumor DNA, identifies up to 34 unique cancer mutations, and encodes them into a custom mRNA vaccine. Once injected, the vaccine trains the immune system to recognize and attack those specific mutations. Keytruda then removes the immune checkpoint blockade, allowing T-cells to destroy cancer cells. This is the first Phase 3 proof that personalized mRNA cancer therapy works.

What happens next

Merck and Moderna plan to present full data at an upcoming international medical conference and begin regulatory submissions within months. The Phase 3 trial will continue to measure overall survival benefits. CEO Stephane Bancel called the results “a landmark moment for adjuvant melanoma treatment” and “a big moment for medicine, a big moment for patients.”

What Meyka data shows

Meyka grades MRNA a B with a 12-month forecast of $58.61, well below Wednesday’s close. The stock’s RSI at 92 signals severe overbought conditions, while five analysts rate it Buy and six rate it Hold. The 177% single-day surge reflects euphoria over the trial win, but Meyka’s valuation metrics remain stretched at a 30.4x price-to-sales ratio and negative earnings yield.

Final Thoughts

Moderna’s melanoma vaccine win is a genuine scientific breakthrough, but the stock’s 177% rally in one day has pushed valuations into extreme territory. Meyka’s B grade and $58.61 forecast suggest the market has priced in years of upside already. Investors should wait for regulatory clarity and overall survival data before chasing the stock at these levels.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes.  Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.